Rajat Bose of rajatkbose.com told CNBC-TV18, "I personally hold Biocon stock in my portfolio. At the moment, unless you are a long-term investor, you better not stay in Biocon. If you are a long-term investor and willing to bet on the company's prospects then put a cautionary stoploss of Rs 325 and carry on with it but knowing fully well that other pharma companies might actually perform much better than Biocon. So that is the kind of scenario that you can envisage for Biocon."
At 14:58 hrs Biocon was quoting at Rs 365.35, down Rs 1.40, or 0.38 percent on the BSE.
The share touched its 52-week high Rs 424.15 and 52-week low Rs 267.81 on 19 July, 2017 and 09 November, 2016, respectively.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!